“Fentanyl is killing Americans at an alarming rate, and too many Long Island families have felt the devastating impact firsthand. That’s fwhy I proudly voted for S. 331, the Senate’s bipartisan version of the HALT Fentanyl Act—because we need strong, unified action to combat this crisis,” said Rep. LaLota. “With over 48,000 fentanyl-related deaths last year, this bill gives law enforcement the tools they need to prosecute traffickers, disrupt supply chains, and impose harsher penalties on those spreading this poison. I’ll continue supporting serious, bipartisan efforts to protect Suffolk County families and save lives.”
The bipartisan HALT Fentanyl Act (S. 331) permanently classifies fentanyl-related substances (FRS) as Schedule I drugs under the Controlled Substances Act. This allows Law Enforcement to treat all fentanyl analogues with the same seriousness as fentanyl itself, preventing traffickers from evading prosecution by tweaking chemical formulas. The bill also applies existing fentanyl trafficking penalties, including mandatory minimum sentences, to these related substances.
To support scientific advancement, the bill streamlines the process for researching Schedule I substances like FRS. It simplifies registration requirements and allows researchers to study multiple substances under a single license. These provisions ensure that public health and law enforcement agencies can better understand and respond to emerging synthetic opioids.
Congressman LaLota voted for the HALT Fentanyl Act last Congress on May 25, 2023, and is the sponsor of the bipartisan Detect Fentanyl and Xylazine Act, which was signed into law on December 23, 2024. The legislation enhances detection of these deadly drugs in the supply chain to better support interdiction and public health efforts.